肿瘤药物研发中的预测性生物标志物：治疗行业视角 - Suppr

Suppr

超能文献

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

作者信息

Fine B M, Amler L

机构信息

Genentech, Inc., South San Francisco, California, USA.

出版信息

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

DOI:10.1038/clpt.2009.9

PMID:19295504

Abstract

摘要

相似文献

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. doi: 10.1158/1078-0432.CCR-03-0785.

SRC as a potential therapeutic target in solid tumor oncology.

Clin Adv Hematol Oncol. 2004 Jul;2(7):435-7.

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.

Expert Rev Anticancer Ther. 2005 Aug;5(4):727-35. doi: 10.1586/14737140.5.4.727.

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.

Clin Cancer Res. 2003 May;9(5):1579-89.

Targeted therapies: aiming for the bull's-eye.

ONS Connect. 2007 Jul;22(7):8-12.

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

Anticancer Drugs. 2009 Nov;20(10):851-5. doi: 10.1097/CAD.0b013e3283330590.

Foreword.

Curr Probl Cancer. 2009 Jul-Aug;33(4):244. doi: 10.1016/j.currproblcancer.2009.10.001.

American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.

IDrugs. 2009 Jun;12(6):335-8.

引用本文的文献

Hypoxia-targeted drug delivery.

Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a.

Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses.

Anal Bioanal Chem. 2013 May;405(14):4953-8. doi: 10.1007/s00216-013-6908-z. Epub 2013 Mar 23.

Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Oncologist. 2013;18(1):104-11. doi: 10.1634/theoncologist.2012-0235. Epub 2012 Dec 20.

Quantifying factors for the success of stratified medicine.

Nat Rev Drug Discov. 2011 Oct 31;10(11):817-33. doi: 10.1038/nrd3557.

Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96. doi: 10.1038/nrclinonc.2011.121.

Molecular therapy drives patient-centric health care paradigms.

Clin Transl Sci. 2010 Aug;3(4):170-1. doi: 10.1111/j.1752-8062.2010.00203.x.

Bayesian adaptive randomization designs for targeted agent development.

Clin Trials. 2010 Oct;7(5):584-96. doi: 10.1177/1740774510373120. Epub 2010 Jun 22.

The evolving role of mass spectrometry in cancer biomarker discovery.

Cancer Biol Ther. 2009 Jun;8(12):1083-94. doi: 10.4161/cbt.8.12.8634. Epub 2009 Jun 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

作者信息

Fine B M, Amler L

机构信息

Genentech, Inc., South San Francisco, California, USA.

出版信息

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

DOI:10.1038/clpt.2009.9

PMID:19295504

Abstract

摘要

相似文献

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

Clin Pharmacol Ther. 2009 May;85(5):535-8. doi: 10.1038/clpt.2009.9. Epub 2009 Mar 18.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. doi: 10.1158/1078-0432.CCR-03-0785.

SRC as a potential therapeutic target in solid tumor oncology.

Clin Adv Hematol Oncol. 2004 Jul;2(7):435-7.

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.

Expert Rev Anticancer Ther. 2005 Aug;5(4):727-35. doi: 10.1586/14737140.5.4.727.

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.

Clin Cancer Res. 2003 May;9(5):1579-89.

Targeted therapies: aiming for the bull's-eye.

ONS Connect. 2007 Jul;22(7):8-12.

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

Anticancer Drugs. 2009 Nov;20(10):851-5. doi: 10.1097/CAD.0b013e3283330590.

Foreword.

Curr Probl Cancer. 2009 Jul-Aug;33(4):244. doi: 10.1016/j.currproblcancer.2009.10.001.

American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.

IDrugs. 2009 Jun;12(6):335-8.

引用本文的文献

Hypoxia-targeted drug delivery.

Chem Soc Rev. 2019 Feb 4;48(3):771-813. doi: 10.1039/c8cs00304a.

Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses.

Anal Bioanal Chem. 2013 May;405(14):4953-8. doi: 10.1007/s00216-013-6908-z. Epub 2013 Mar 23.

Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Oncologist. 2013;18(1):104-11. doi: 10.1634/theoncologist.2012-0235. Epub 2012 Dec 20.

Quantifying factors for the success of stratified medicine.

Nat Rev Drug Discov. 2011 Oct 31;10(11):817-33. doi: 10.1038/nrd3557.

Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96. doi: 10.1038/nrclinonc.2011.121.

Molecular therapy drives patient-centric health care paradigms.

Clin Transl Sci. 2010 Aug;3(4):170-1. doi: 10.1111/j.1752-8062.2010.00203.x.

Bayesian adaptive randomization designs for targeted agent development.

Clin Trials. 2010 Oct;7(5):584-96. doi: 10.1177/1740774510373120. Epub 2010 Jun 22.

The evolving role of mass spectrometry in cancer biomarker discovery.

Cancer Biol Ther. 2009 Jun;8(12):1083-94. doi: 10.4161/cbt.8.12.8634. Epub 2009 Jun 6.